ETCTN 10483: Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR3/2 genetic alterations (GAs).

Authors :: Jain, Rohit K.
Ong, Faustine
Faltas, Bishoy Morris
Tagawa, Scott T.
Jiang, Di Maria
Heiligh, Jazlyn
Naqvi, Syeda Mahrukh Hussnain
Kim, Youngchul
Pelosof, Lorraine Cheryl
Yang, Yuanquan
Graham, Laura
Arafat, Waddah
Synold, Timothy Walter
Chatwal, Monica Sheila
Zhang, Jingsong
Chadha, Jus
Sonpavde, Guru P.
Source :: Journal of Clinical Oncology; 2/20/2025 Supplement 5, Vol. 43, p808-808, 242p
Publication Year :: 2025

Full Text Access

Tools